Observational study to evalute patient satisfaction with different oral cannabis products - SATUR

Avextra Pharma GmbH0 个研究点目标入组 500 人开始时间: 2023年10月17日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. Patients of any gender and ethnicity aged 18 years or older (both cannabis-naïve and cannabis-experienced).
•2. Documented diagnosis of a condition for which cannabis as a medicine (CAM) is indicated (and has been and is being used according to the 2022 BfArM companion survey), e.g. for (but not limited to):
•- Chronic musculoskeletal pain
•- Neuropathic pain
•- Chronic tumour-related pain
•- Use in palliative care (e.g. inappetence, nausea, pain)
•- Spasticity, e.g. caused by multiple sclerosis
•- anorexia
•- Gastrointestinal diseases (e.g. Crohn's disease, ulcerative colitis)
•- Sleep disorders
•- Psychiatric diseases (e.g. ADHD, tic disorder, PTSD)
•- Neurological diseases (e.g. epilepsy, restless legs syndrome)
•- Headaches (migraine, cluster headache, tension headache)
•- Chronic lower abdominal pain (e.g. endometriosis)
•3. Treatment with a cannabinoid justified on the basis of a justified assessment by the physician, weighing of the expected side effects and taking into account the state of the disease.

•1. Any other condition, disorder or observation which, in the opinion of the investigator, would interfere with the participant's ability to complete the study survey.
•2. Hypersensitivity/allergy to THC or CBD or the other components of the respective dosage form.
•3. Psychiatric illness related to schizophrenia/psychosis.

发起方

Avextra Pharma GmbH